Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 9/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20653655 | 0.93 | IDO1 (0.46) | IDO1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL19900660 | 0.85 | IDO1 (0.51) | IDO1 | |
| SCHEMBL19900662 | 0.85 | IDO1 (0.51) | IDO1 | |
| SCHEMBL19661023 | 0.85 | IDO1 (0.51) | IDO1 | |
| SCHEMBL21098833 | 0.84 | IDO1 (0.43) | IDO1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL2757625 | 0.84 | IDO1 (0.52) | IDO1MEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL179218 | 0.84 | IDO1 (0.62) | IDO1 | |
| SCHEMBL20198906 | 0.84 | IDO1 (0.50) | IDO1MEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL179217 | 0.83 | IDO1 (0.56) | IDO1 | |
| SCHEMBL179222 | 0.83 | IDO1 (0.46) | IDO1MEN1KMT2ASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185439-A1 | RADIOFLUORINATED CARBOXIMIDAMIDES AS IDO TARGETING PET TRACER FOR CANCER IMAGING | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2019-06-20 | — | — | US | disclosed |
| WO-2018039430-A1 | RADIOFLUORINATED CARBOXIMIDAMIDES AS IDO TARGETING PET TRACER FOR CANCER IMAGING | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185439-A1 | RADIOFLUORINATED CARBOXIMIDAMIDES AS IDO TARGETING PET TRACER FOR CANCER IMAGING | IDO1, IDO2, IFNG | IDO1 1/4885MEN1 1876/4885KMT2A 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.